奥克列珠单抗
医学
多发性硬化
美罗华
队列
内科学
肿瘤科
CD20
药品
物理疗法
免疫学
药理学
淋巴瘤
作者
M. Hay,Fabien Rollot,Romain Casey,Anne Kerbrat,Gilles Edan,Guillaume Mathey,Pierre Labauge,J. de Sèze,Sandra Vukusic,David Laplaud,Caroline Papeix,Thibault Moreau,Éric Thouvenot,Gilles Defer,Christine Lebrun‐Frénay,Jonathan Ciron,Eric Berger,Bruno Stankoff,Pierre Clavelou,Élisabeth Maillart
出处
期刊:Neurology
[Lippincott Williams & Wilkins]
日期:2024-09-25
卷期号:103 (8): e209886-e209886
被引量:1
标识
DOI:10.1212/wnl.0000000000209886
摘要
This study provides Class III evidence that anti-CD20 therapy of previously untreated patients with PPMS was not superior to no therapy in delaying time to first CDP.
科研通智能强力驱动
Strongly Powered by AbleSci AI